Shares of gene therapy maker uniQure surged 66% after the U.S. Food and Drug Administration delivered what Endpoints News described as "surprise good news": the company is now one step closer to marketing its treatment for Huntington's disease.
According to Endpoints News, the FDA has given uniQure a green light to seek accelerated approval for the therapy. Endpoints framed this as the agency's "second reversal" on the matter, signaling a notable shift in how regulators are approaching the case.
Endpoints News also reported that "regulatory flexibility appears to be back on the FDA's menu" following the departures of Marty Makary and Vinay Prasad from the agency. In other words, the change in personnel appears to have coincided with a more accommodating stance toward uniQure's path forward.
Huntington's disease is a devastating, inherited neurological disorder, and there are currently very limited options for slowing it. A gene therapy that wins accelerated approval could reach patients faster than a treatment forced to wait for the full, traditional approval process.
For uniQure, the dramatic stock jump reflects how much investors had riding on the FDA's decision. The accelerated approval pathway is designed to speed promising therapies for serious conditions to market, though it typically comes with requirements to confirm benefits in later studies.
Why it matters: the FDA's reversal not only revives a potential treatment for a fatal disease with few options, but also offers an early signal that the agency may be loosening its regulatory posture after a leadership shake-up.